PEOPLES INVESTING $2 MIL. TO START PATIENT DRUG INFORMATION PAMPHLETS
PEOPLES INVESTING $2 MIL. TO START PATIENT DRUG INFORMATION PAMPHLETS and support natl. advertising campaign in newspapers, radio, and television, the chain's Chairman Sheldon Fantle declared at an Oct. 3 press briefing to announce the new patient education program. The campaign, called "Help Your Health: You Can, We Can," is designed "to help consumers help themselves by bringing them vital information on health care," Fantle said. Six brochures have been developed, with more to be distributed subsequently, Fantle continued. The subjects addressed by the first six pamphlets are "Understanding Your Medications," antibiotics, antihistamines, tranquilizers, drugs in pregnancy, and home diagnostic test kits. Fantle added that the information in the pamphlets was developed with the assistance of FDA and the Natl. Council on Patient Information and Education. Help Your Health" is the third public health education campaign the chain has launched with the help of FDA, Fantle noted. Peoples distributed "over 5 mil. pamphlets" in their "Living with Aging" and "Spot It, Stop It" drug abuse campaigns. * The program also includes the reconfiguration of Peoples' pharmacy departments "to make the pharmacist more accessible to consumers," Fantle noted. Peoples, Lane, Lee, Reed, and Rea & Derick stores will be redesigned so that fewer barriers separate pharmacists from patients, he said. In addition, "consulting booths" are being installed "in the corner of the Rx room," where pharmacists and patients "can talk in privacy relative to the medication," Fantle said. Likening the concept to confessionals -- "the pharmacist sits on one side and the patient on the other" -- he added that Indianapollis-area stores had already been converted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth